# Jens Holstein, Chief Financial Officer

## Meet the Team | June 25, 2019

# This presentation includes forward-looking statements.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including its financial guidance for 2019, the commencement, timing and results of clinical trials and release of clinical data both in respect of its proprietary product candidates and of product candidates of its collaborators, the development of commercial capabilities, in particular with respect to tafasitamab (MOR208) and the transition of MorphoSys to a fully integrated biopharmaceutical company, interaction with regulators, including the potential approval of MorphoSys's current or future drug candidates, including discussions with the FDA regarding the potential approval to market tafasitamab, the expected time of launch of tafasitamab, and expected royalty and milestone payments in connection with MorphoSys's collaborations. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys's results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are that MorphoSys's expectations regarding its 2019 results of operations may be incorrect, MorphoSys's expectations regarding its development programs may be incorrect, the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that MorphoSys may fail to obtain regulatory approval for tafasitamab and that data from MorphoSys's ongoing clinical research programs may not support registration or further development of its product candidates due to safety, efficacy or other reasons), MorphoSys's reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys's Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

The compounds discussed in this slide presentation are investigational products being developed by MorphoSys and its partners and are not currently approved by the U.S. Food and Drug Administration (FDA), European Medicine Agency (EMA) or any other regulatory authority (except for guselkumab/Tremfya®). Any shown cross-trial comparison between MorphoSys-own investigational products and literature data have significant limitations. Such data comparisons have been prepared at the request of, and for the sole benefit of, the investor community.

# Our financial strength is the basis for our new growth trajectory

# Key Financial Figures

## Well positioned to execute strategy and drive value

| In € million | FY 2018 (As of March 13, 2019) | Q1 2019 (As of May 7, 2019) | Guidance 2019 (As of March 13, 2019) |
|---|---|---|---|
| Group Revenues[1)] | 76.4 | 13.5 | 43 to 50[1)] |
| Proprietary R&D Expenses (incl. Technology Development) | 98.3 | 22.6 | 95 to 105 |
| EBIT | -59.1 | -23.6 | -127 to -137 |
| Cash position | 454.7 | 431.2 | |

Total ordinary shares issued as of May 31, 2019: 31,839,572

1) Revenues are expected to include royalty income from Tremfya® ranging from EUR 23-30 million at constant USD exchange rate.

# Financial Strategy



## Solid Cash Position

Leverage increasing royalty streams and milestone payments in the years to come

## Prudent Capital Allocation

Invest in proprietary portfolio, especially tafasitamab and U.S. commercial build-up

## First Proprietary Product Launch

Capture growth opportunities in global DLBCL by intending to invest broader in tafasitamab

## Prospective Cash Generation

Build on revenues from tafasitamab and partnered product sales as well as partnering deals

# Solid Cash Position

## Solid financial 2019 goals with further upside potential



# Prudent Capital Allocation

## Invest in proprietary portfolio and U.S. commercial build-up[1)]

Total FY 2018: €136.5m




Total Q1 2019: €37.3m




R&D Expenses | Total Costs Commercial Build-Up | Other Headquarter Costs

1) In € million

# Strategic Investments

## Invest in proprietary portfolio and U.S. commercial build-up




1) Excluding potential partnering or in-licensing deal

# First Proprietary Product Launch

## Capture growth opportunities in global DLBCL market




1) Combined literature and analyst estimates

# First Proprietary Product Launch

## Capture growth opportunities in global DLBCL market[1)]

Potential market share in 1st line DLBCL[2)]




Potential market share in 2nd line DLBCL[2)]




1) Combined literature and analyst estimates (illustrative) 2) Subject to regulatory approval

# Opportunity for Tafasitamab in r/r DLBCL

## Addressable U.S. market: ~10,000 patients as of 2018




Source: DRG Epidemiology data; Kantar Market Research (TPP testing 2018), Friedberg et al., 2011
*Depending on label

# Opportunity for Tafasitamab in r/r DLBCL

## Addressable EU market: ~6,500 patients as of 2018




Source: DRG Epidemiology data; Kantar Market Research (TPP testing 2018), Friedberg et al., 2011
*Depending on label

# Prospective Cash Generation

## Build on revenues from own and partnered product sales




- Potential for tafasitamab in further settings (1st line DLBCL, additional indications)
- Proprietary pipeline programs and potential in-licensed projects
- Vision: Adding compounds following tafasitamab for commercialization

- U.S. launch of tafasitamab in r/r DLBCL mid-2020, subject to FDA approval
- Preparation for tafasitamab EU approval

- Group revenues in 2019 expected between €43 to 50m

# SUMMARY

Solid financial position to fully explore and invest in the value of our proprietary portfolio

Multiple cash flow contributions to support broadening of tafasitamab

Increasing opportunities based on a significantly growing global DLBCL market